Clinical Trial Update: Dose Ranging Study Of Bococizumab (PF-04950615; RN316) In Hypercholesterolemic Japanese Subjects [Phase 2]

View source ↗

Summary

Pfizer conducted a Phase 2 dose-ranging study of bococizumab in Japanese patients with hypercholesterolemia; the trial has completed and results have been poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypercholesterolemia

Drugs mentioned

• bococizumab (PF-04950615) (bococizumab)

Snippet

Sponsor: Pfizer | Conditions: Hypercholesterolemia | Phase 2 | Status: COMPLETED | Results posted: 2019-02-08